Toronto, Ontario – September 24, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today that McGill University Health Centre (“MUHC”) has re-commenced new patient enrollment and treatment in the Company’s Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”). Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment. Efficacy to date at the 90 day assessment includes: 3 out of 12 patients (25%) have demonstrated a Complete Response (“CR”) … Read More
Theralase® Releases 2Q2020 Financial Statements
Toronto, Ontario – August 28, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses released its unaudited interim consolidated condensed 2Q2020 financial statements. Financial Highlights: Total revenue for the six-month period ended June 30, 2020, decreased to $293,453 from $370,436 for the same period in 2019, a 21% decrease. In Canada, revenue decreased 23% to $255,146 in 2020 from $333,047 in 2019. In the US, revenue decreased 49% to 12,267 in 2020 from $23,926 in 2019. International revenue increased 93% to $26,041 for 2020 from $13,463 in 2019. The decrease in total revenue in 2020 is primarily attributed to the COVID-19 pandemic as a majority of health care practitioners elected to temporarily close their … Read More
Theralase Amends the Company’s Standard By-Laws
Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses, announced today that the board of directors of Theralase has approved amendments to the Company’s standard by-laws. The amendments to the Company’s standard by-laws include certain housekeeping amendments and updates to the general by-laws in order to better align with the current provisions of the Canada Business Corporations Act and corporate governance standards. The amended by-laws remain subject to the approval of the TSX Venture Exchange and will be put before shareholders at the Company’s upcoming annual and special meeting of shareholders to be held on September 24, 2020 for approval. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the … Read More
Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy
Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that it has executed a Sponsored Research Agreement (“SRA”) with the University of Manitoba (“UM”) Medical Microbiology department to commence development of a coronavirus vaccine and therapy utilizing Theralase’s patented and proprietary PDCs. According to the SRA, UM will conduct experiments in conjunction with Theralase for the research and development of a coronavirus vaccine and therapeutic to be further evaluated in animal then human clinical testing in 2021. Dr. Kevin Coombs, PhD, Professor, Department of Medical Microbiology, will lead the research for the University of Manitoba. One of Dr. Coombs’ interests is the investigation of how COVID-19 impacts genes and proteins in lung cells. In … Read More
Canadian Clinical Study Sites Re-Commence Bladder Cancer Study
Toronto, Ontario – August 12, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today that three out of four of its Canadian clinical study sites have re-commenced new patient enrollment and treatment in the Company’s Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”). Specifically: Study Site Location Site Status University Health Network (“UHN”) Toronto, Ontario Enrolling London Health Sciences Centre (“LHSC”), London, Ontario Enrolling Nova Scotia Health Authority (“NSHA”) Halifax, Nova Scotia Enrolling McGill University Health Centre (“MUHC”) Montreal, Quebec COVID-19 Hold On a go forward basis, all future and existing patients to be enrolled and treated (initial and second treatment) in Study II will be treated using the Study II treatment optimizations as communicated via press release on July 30, 2020, specifically: … Read More
Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”) Progress
Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment Toronto, Ontario – July 30, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to provide an update on its Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”). The primary purpose of Study II is to discover if the TLD-1433 (“Study Drug”) combined with TLC-3200 (“Study Device”) (collectively the “Study Treatment”) are effective in the destruction of Bacillus Calmette-Guérin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”). All Canadian clinical study sites currently remain closed for new patient enrollment and treatment; however, Canadian clinical study sites, who have already enrolled and treated … Read More
Theralase Announces Management Information Circular and Annual General Meeting Postponement Due to COVID-19
Toronto, Ontario – June 30, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers announces that after careful consideration the Company has decided to postpone its management information circular and the Annual General Meeting (“AGM”). In light of the COVID-19 pandemic and the restrictions on public gatherings enacted by both the Federal and Provincial governments in Canada to help protect the health and safety of its shareholders, employees and stakeholders, Theralase has elected to delay holding its 2020 AGM. The Company will be relying on the relief granted under Ontario Instrument 51-504 – Temporary Exemptions from Certain Requirements to File or Send Securityholder Materials, in connection with delaying the public filing of its executive compensation disclosure past the … Read More
Theralase Receives FDA IND Authorization
Toronto, Ontario – May 19, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to announce today that the Company has received Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) authorization to conduct a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) in the United States. Study II, entitled, “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Bacillus Calmette-Guerin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Patients or Patients who are Intolerant to BCG Therapy” was successfully launched in Canada at 4 clinical study sites (with 1 additional clinical study site in advanced negotiation) and now with FDA IND authorization, the Company plans to launch approximately 15 clinical study sites … Read More
Theralase Releases 2019 Financial Results
Toronto, Ontario – April 29, 2020, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, releases the audited annual consolidated financial statements for the year ended December 31, 2019. Financial Highlights: Total revenue for the year ended December 31, 2019 decreased $964,051 from $1,734,073 for the same period in 2018, a 44% decrease. The TLC-2000 represented 66% of sales in 2019 and 70% of sales in 2018. In Canada, revenue decreased 31% to $835,403 from $1,205,312. In the US, revenue decreased 68% to $96,574 from $304,785 and international revenue decreased 86% to $32,074 from $223,975. The decrease in total revenue in 2019 is due to the restructuring of the sales and marketing departments resulting in the resignation and/or termination of certain sales … Read More
Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study
Toronto, Ontario – March 20, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, has been notified by all of its Canadian clinical study sites that enrollment of new patients and conducting the first treatment procedure in the Company’s Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) has been temporarily placed on hold pending resolution of the coronavirus (“COVID-19”) global pandemic. Due to the global spread of COVID-19 and the uncertainty associated with the virus, the Company is in agreement with the clinical study site’s decision and with provincial and federal government recommendations concerning social distancing, to minimize hospital admittance to only patients with an emergency need. The clinical study sites have elected to temporarily halt enrollment and first treatment of patients in … Read More